HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Increased A3AR-dependent vasoconstriction in diabetic mice is promoted by myeloperoxidase.

Abstract
Vascular dysfunction importantly contributes to mortality and morbidity in various cardiac and metabolic diseases. Among endogenous molecules regulating vascular tone is adenosine, with the adenosine A3 receptor (A3AR) exerting cardioprotective properties in ischemia and reperfusion. However, overexpression of A3AR is suggested to result in vascular dysfunction and inflammation. The leukocyte enzyme myeloperoxidase (MPO) is an important modulator of vascular function with nitric oxide-consuming and proinflammatory properties. Increased MPO plasma levels are observed in patients with cardiovascular disorders like heart failure, acute coronary syndromes, and arrhythmias. Given that vascular dysfunction and inflammation are also hallmarks of diabetes, the role of MPO in adenosine-dependent vasomotor function was investigated in a murine model of diabetes mellitus. Wild-type (WT) and MPO-deficient (Mpo) mice were treated with Streptozotocin (STZ), which induced an increase of MPO plasma levels in WT mice and led to enhanced aortic superoxide generation as assessed by dihydroethidium staining in STZ-treated WT mice as compared with controls. The vasoconstriction of aortic segments in response to the A3AR agonist Cl-IB-MECA (2-Chloro-N6-(3-iodobenzyl)-N-methyl-5-carbamoyladenosine) as determined by isometric force measurements was augmented in diabetic WT as compared with diabetic Mpo mice. Moreover, A3AR protein expression was enhanced in STZ-treated mice but was attenuated by MPO deficiency. The current data reveal an MPO-mediated increase of vascular A3AR expression under diabetic conditions, which leads to enhanced vasoconstriction in response to A3AR agonists and discloses an additional mechanism of MPO-mediated vascular dysfunction.
AuthorsShamama Nishat, Anna Klinke, Stephan Baldus, Luqman Ahmad Khan, Seemi Farhat Basir
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 64 Issue 5 Pg. 465-72 (Nov 2014) ISSN: 1533-4023 [Electronic] United States
PMID25000478 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adenosine A3 Receptor Agonists
  • Receptor, Adenosine A3
  • Superoxides
  • Streptozocin
  • Peroxidase
  • Adenosine
  • 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
Topics
  • Adenosine (analogs & derivatives, pharmacology)
  • Adenosine A3 Receptor Agonists (pharmacology)
  • Animals
  • Aorta (metabolism)
  • Diabetes Mellitus, Experimental (physiopathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Peroxidase (genetics, metabolism)
  • Receptor, Adenosine A3 (drug effects, metabolism)
  • Streptozocin
  • Superoxides (metabolism)
  • Vasoconstriction (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: